Supplementary Material for: Clinicians' Attitudes toward General Screening of the Ashkenazi-Jewish Population for Prevalent Founder <b><i>BRCA1/2</i></b> and <b><i>LRRK2</i></b> Mutations
2013-06-28T00:00:00Z (GMT) by
<b><i>Aims:</i></b> Advances in genomics may eventually lead to genetic susceptibility screening of the general population, regardless of a personal or familial history of the disease in question. Yet, little is known about clinicians' attitudes toward such programs. We explored attitudes of family practitioners, medical geneticists and genetic counselors toward genetic screening of the general Ashkenazi-Jewish population for the common founder mutations in <i>BRCA1/2</i> and <i>LRRK2</i> genes (which increase the risk of hereditary breast/ovarian cancers and Parkinson's disease, respectively). <b><i>Methods:</i></b> Participants (n = 204) completed a specially designed questionnaire, distributed by e-mail, regular mail or in-person. <b><i>Results:</i></b> Slightly more than half (52%) were in favor of <i>BRCA</i> screening, while the vast majority (86%) opposed to <i>LRRK2</i> screening. About two-thirds (68%) of the respondents supported pre-test genetic counseling. Attitudes were largely independent of professional background and sociodemographic characteristics, though a correlation was found with personal interest in genetic self-testing for the above genes. Adverse psychological impact and discrimination in insurance and employment were the major concerns cited by respondents with regard to screening programs. <b><i>Conclusion:</i></b> Our findings suggest that the availability of measures for prevention and/or treatment is a major factor in the attitudes of healthcare providers toward population screening for late-onset conditions.